Literature DB >> 9190892

Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4.

M Wang1, Y E Liu, J Greene, S Sheng, A Fuchs, E M Rosen, Y E Shi.   

Abstract

We recently identified, cloned, and characterized a novel human tissue inhibitor of metalloproteinases-4, TIMP-4 (Greene et al., 1996). To determine if TIMP-4 can modulate the in vivo growth of human breast cancers, we transfected a full-length TIMP-4 cDNA into MDA-MB-435 human breast cancer cells and studied the orthotopic growth of TIMP-4-transfected (TIMP4-435) versus control (neo-435) clones in the mammary fat pad of athymic nude mice. TIMP4-435 clones expressed TIMP-4 mRNA and produced anti-metalloproteinase (MMP) activity, while neo-435 clones did not express TIMP-4 mRNA or produce detectable anti-MMP activity. Overexpression of TIMP-4 inhibited the invasion potential of the cells in the in vitro invasion assay. When injected orthotopically into nude mice, TIMP-4 transfectants were significantly inhibited in tumor growth by 4-10-fold in primary tumor volumes; and in an axillary lymph node and lung metastasis as compared with controls. These results suggest the therapeutic potential of TIMP-4 in treating cancer malignant progression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9190892     DOI: 10.1038/sj.onc.1201245

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  38 in total

Review 1.  A case of tumor betrayal: biphasic effects of TIMP-1 on Burkitt's lymphoma.

Authors:  L Yan; M A Moses
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

Review 2.  The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.

Authors:  G Cox; W P Steward; K J O'Byrne
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

3.  Focal adhesion kinase mediates TGF-beta1-induced renal tubular epithelial-to-mesenchymal transition in vitro.

Authors:  Bingqing Deng; Xiao Yang; Jianshe Liu; Fangfang He; Zhonghua Zhu; Chun Zhang
Journal:  Mol Cell Biochem       Date:  2010-02-23       Impact factor: 3.396

4.  Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model.

Authors:  Odete Mendes; Hun-Taek Kim; George Stoica
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

Review 5.  Computational sequence analysis of the tissue inhibitor of metalloproteinase family.

Authors:  D A Douglas; Y E Shi; Q A Sang
Journal:  J Protein Chem       Date:  1997-05

6.  Suppression of breast cancer growth and metastasis by a serpin myoepithelium-derived serine proteinase inhibitor expressed in the mammary myoepithelial cells.

Authors:  G Xiao; Y E Liu; R Gentz; Q A Sang; J Ni; I D Goldberg; Y E Shi
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

7.  TIMP-3 -1296 T>C and TIMP-4 -55 T>C gene polymorphisms play a role in the susceptibility of hepatocellular carcinoma among women.

Authors:  Hsiu-Ting Tsai; Ming-Ju Hsieh; Hui-Ling Chiou; Hsiang-Lin Lee; Min-Chieh Hsin; Yi-Sheng Liou; Chen-Chieh Yang; Shun-Fa Yang; Wu-Hsien Kuo
Journal:  Tumour Biol       Date:  2014-06-07

8.  Dose-dependent benefits of quercetin on tumorigenesis in the C3(1)/SV40Tag transgenic mouse model of breast cancer.

Authors:  Jl Steiner; Jm Davis; Jl McClellan; Rt Enos; Ja Carson; R Fayad; M Nagarkatti; Ps Nagarkatti; D Altomare; Ke Creek; Ea Murphy
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

9.  Tissue inhibitor of metalloproteinase-4 is elevated in early-stage breast cancers with accelerated progression and poor clinical course.

Authors:  Michaelann Liss; Nandhini Sreedhar; Albert Keshgegian; Guido Sauter; Michael R Chernick; George C Prendergast; U Margaretha Wallon
Journal:  Am J Pathol       Date:  2009-08-21       Impact factor: 4.307

10.  Deregulated activation of matriptase in breast cancer cells.

Authors:  Christelle M Benaud; Michael Oberst; Robert B Dickson; Chen-Yong Lin
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.